

Figure S1. Cumulative incidence of non-CV death (panel A), CV death (panel B), MACE (panel C) and HHF (panel D) according to Copeptin level quintile derived from the unadjusted cause-specific hazard estimates (model A) by application of the Aalen-Johansen estimator




Figure S2. Cumulative incidence of non-CV death (panel A), CV death (panel B), MACE (panel C) and HHF (panel D) according to MR-proANP level quintile derived from the unadjusted cause-specific hazard estimates (model A) by application of the Aalen-Johansen estimator




Figure S3. Cumulative incidence of non-CV death (panel A), CV death (panel B), MACE (panel C) and HHF (panel D) according to NT-proBNP level quintile derived from the unadjusted cause-specific hazard estimates (model A) by application of the Aalen-Johansen estimator




Table S1 Demographics and clinical parameters at baseline stratified by MR-proANP quintiles

| | Total Cohort | MR-proANP (pmol/l) | | | | |
|--|--------------|--------------------|----------------------|-----------------------|-----------------------|--------------------|
| | | Q1 (≤ 69) | Q2 (> 69 - ≤ 102) | Q3 (> 102 - ≤ 144) | Q4 (> 144 - ≤ 213) | Q5 (> 213) |
| N (%) | 4417 | 843 (19.1) | 883 (20.0) | 891 (20.2) | 899 (20.4) | 901 (20.4) |
| Demographics | | | | | | |
| Age (ys) | 61 ± 12 | 53.4 ± 13.4 | 57.9 ± 11.4 | 61.9 ± 10.5 | 64.0 ± 9.0 | 66.0 ± 8.2 |
| Male | 2681 (61) | 534 (63) | 502 (57) | 501 (56) | 546 (61) | 598 (66) |
| Regional center | | | | | | |
| AA – Aachen | 446 (10) | 76 (9) | 74 (8) | 91 (10) | 95 (11) | 110 (12) |
| BE – Berlin | 372 (8) | 63 (7) | 68 (8) | 69 (8) | 87 (10) | 85 (9) |
| ER - Erlangen | 801 (18) | 182 (22) | 160 (18) | 163 (18) | 139 (15) | 157 (17) |
| FR – Freiburg | 300 (7) | 60 (7) | 71 (8) | 512 (6) | 62 (7) | 56 (6) |
| HA - Hannover | 376 (8) | 76 (9) | 72 (8) | 78 (9) | 74 (8) | 76 (8) |
| HE – Heidelberg | 404 (9) | 68 (8) | 79 (9) | 74 (8) | 94 (10) | 89 (10) |
| JE – Jena | 575 (13) | 91 (11) | 123 (14) | 126 (14) | 113 (13) | 122 (14) |
| MU – München | 425 (10) | 96 (11) | 88 (10) | 100 (11) | 83 (9) | 58 (6) |
| WU - Würzburg | 718 (16) | 131 (16) | 148 (17) | 139 (16) | 152 (17) | 148 (16) |
| Laboratory Measures | | | | | | |
| eGFR (ml/min per 1.73 m ²) | 49 ± 17 | 60.8 ± 22.0 | 53.2 ± 16.2 | 48.3 ± 14.4 | 43.9 ± 12.6 | 38.8 ± 11.3 |
| UACR (mg/g) | 47 (9-366) | 52.4 (7.5-498.6) | 33.9 (6.7-284.0) | 30.6 (8.8-218.2) | 46.5 (9.8-309.7) | 85.8 (15.8-562.7) |
| hsCRP (mg/dl) | 2 (1-5) | 1.9 (1.0-4.4) | 2.1 (1.0-4.8) | 2.2 (1.0-4.7) | 2.4 (1.1-5.3) | 2.9 (1.3-6.6) |
| LDL cholesterol (mg/dl) | 113 (88-143) | 122.6 (96.1-149.6) | 118.1 (93.5-142.7) | 114.0 (88.6-145.9) | 107.8 (85.5-136.9) | 103.9 (81.3-133.7) |
| HDL cholesterol (mg/dl) | 48 (39-60) | 47.2 (38.3-59.2) | 48.7 (39.5-60.9) | 49.3 (40.3-61.5) | 48.3 (38.9-61.6) | 47.5 (38.6-61.1) |
| CVD risk factors | | | | | | |
| Systolic BP (mmHg) | 140 ± 21 | 135.0 ± 17.1 | 138.3 ± 18.1 | 139.5 ± 19.5 | 142.9 ± 21.2 | 142.9 ± 24.3 |
| Diastolic BP (mmHg) | 79 ± 12 | 81.4 ± 10.9 | 81.0 ± 10.9 | 79.2 ± 11.4 | 78.1 ± 11.9 | 75.9 ± 12.9 |
| BMI (kg/m ²) | 30 ± 6 | 29.8 ± 5.9 | 29.5 ± 5.9 | 30.1 ± 6.1 | 30.1 ± 5.7 | 30.4 ± 6.2 |
| Diabetes | 1645 (37) | 235 (28) | 274 (31) | 345 (39) | 369 (41) | 422 (47) |
| Previous CVD | 1180 (27) | 95 (11) | 154 (17) | 199 (22) | 327 (36) | 405 (45) |

| | | | | | | |
|-----------------------|-----------|----------|----------|----------|----------|----------|
| Heart Failure | 836 (19) | 80 (9) | 104 (12) | 140 (16) | 219 (24) | 293 (33) |
| Smoking history | | | | | | |
| never | 1813 (41) | 336 (40) | 363 (41) | 396 (44) | 376 (42) | 342 (38) |
| former | 1918 (44) | 334 (40) | 362 (41) | 377 (42) | 394 (44) | 451 (50) |
| current | 673 (15) | 170 (20) | 155 (18) | 115 (13) | 126 (14) | 107 (12) |
| Medication Use | | | | | | |
| RASi | 3713 (84) | 704 (84) | 724 (82) | 729 (82) | 784 (87) | 772 (86) |
| Statins | 2155 (49) | 324 (38) | 379 (43) | 428 (48) | 492 (55) | 532 (59) |
| Anti-platelet agents | 1564 (36) | 173 (21) | 266 (30) | 329 (37) | 405 (45) | 391 (43) |
| Beta-blockers | 2480 (57) | 238 (28) | 374 (42) | 492 (55) | 653 (73) | 723 (80) |
| MRA | 364 (8) | 57 (7) | 56 (6) | 68 (8) | 73 (8) | 110 (12) |

Continuous variables are presented as mean and standard deviation or median and interquartile range.

Categorical variables are presented as numbers with percentages in the overall study population.

eGFR=estimated glomerular filtration rate, UACR=urinary albumin excretion rate, hsCRP=high sensitive C-reactive protein, LDL=low density lipoprotein, HDL=high density lipoprotein, BP=blood pressure, BMI=body mass index, CVD=cardiovascular disease, RASi=renin angiotensin system inhibitor, MRA=mineralocorticoid receptor antagonist

Table S2: Demographics and clinical parameters at baseline stratified by NT-proBNP quintiles

| | NT-proBNP (pg/ml) | | | | | |
|--|-------------------|--------------------|----------------------|-----------------------|-----------------------|--------------------|
| | Total Cohort | Q1 (≤ 74) | Q2 (> 74 - ≤ 136) | Q3 (> 136 - ≤ 250) | Q4 (> 250 - ≤ 532) | Q5 (> 532) |
| N (%) | 4417 | 879 (19.9) | 868 (19.7) | 873 (19.8) | 902 (20.4) | 895 (20.3) |
| Demographics | | | | | | |
| Age (ys) | 61 ± 12 | 53.8 ± 12.9 | 59.2 ± 11.4 | 61.1 ± 11.3 | 63.6 ± 9.8 | 65.9 ± 8.0 |
| Male | 2681 (61) | 617 (70) | 503 (58) | 484 (55) | 495 (55) | 582 (65) |
| Reginal center | | | | | | |
| AA – Aachen | 446 (10) | 90 (10) | 86 (10) | 83 (10) | 87 (10) | 100 (11) |
| BE – Berlin | 372 (8) | 63 (7) | 61 (7) | 79 (9) | 96 (11) | 73 (8) |
| ER - Erlangen | 801 (18) | 177 (20) | 160 (18) | 152 (17) | 145 (16) | 167 (19) |
| FR – Freiburg | 300 (7) | 60 (7) | 56 (6) | 48 (6) | 70 (8) | 66 (7) |
| HA - Hannover | 376 (9) | 87 (10) | 73 (8) | 75 (9) | 75 (8) | 66 (7) |
| HE – Heidelberg | 404 (9) | 75 (9) | 72 (8) | 95 (11) | 80 (9) | 82 (9) |
| JE – Jena | 575 (13) | 92 (10) | 118 (14) | 118 (14) | 116 (13) | 131 (15) |
| MU – München | 425 (10) | 96 (11) | 96 (11) | 87 (10) | 87 (10) | 80 (9) |
| WU - Würzburg | 718 (16) | 139 (16) | 146 (17) | 136 (16) | 167 (19) | 130 (15) |
| Laboratory Measures | | | | | | |
| eGFR (ml/min per 1.73 m ²) | 49 ± 17 | 58.4 ± 21.0 | 51.3 ± 16.9 | 48.3 ± 14.9 | 45.5 ± 14.9 | 40.7 ± 13.0 |
| UACR (mg/g) | 47 (9-366) | 52.4 (7.2-416.4) | 37.3 (7.0-276.9) | 34.8 (8.5-318.9) | 41.6 (9.9-305.7) | 77.3 (15.5-531.5) |
| hsCRP (mg/dl) | 2 (1-5) | 1.7 (0.8-3.8) | 2.1 (1.0-4.7) | 2.2 (1.0-4.5) | 2.6 (1.1-5.4) | 3.2 (1.5-7.9) |
| LDL cholesterol (mg/dl) | 113 (88-143) | 122.7 (94.9-148.0) | 118.2 (94.4-147.3) | 113.5 (90.2-142.7) | 110.5 (86.1-140.5) | 101.8 (80.3-131.2) |
| HDL cholesterol (mg/dl) | 48 (39-60) | 46.8 (38.1-57.4) | 48.7 (40.3-60.9) | 49.8 (40.7-62.4) | 49.2 (40.6-62.8) | 47.0 (37.3-59.8) |
| CVD risk factors | | | | | | |
| Systolic BP (mmHg) | 140 ± 21 | 134.8 ± 16.3 | 137.9 ± 19.1 | 138.8 ± 18.8 | 143.1 ± 21.6 | 143.0 ± 24.4 |
| Diastolic BP (mmHg) | 79 ± 12 | 81.4 ± 10.4 | 80.7 ± 11.6 | 78.9 ± 11.4 | 78.3 ± 12.1 | 76.3 ± 12.6 |
| BMI (kg/m ²) | 30 ± 6 | 29.8 ± 5.7 | 29.8 ± 6.1 | 29.5 ± 5.9 | 30.0 ± 6.1 | 30.5 ± 6.2 |
| Diabetes | 1645 (37) | 250 (28) | 258 (30) | 316 (36) | 345 (38) | 476 (53) |
| Previous CVD | 1180 (27) | 92 (10) | 144 (17) | 190 (22) | 314 (35) | 440 (49) |
| Heart Failure | 836 (19) | 68 (8) | 106 (12) | 126 (14) | 210 (23) | 326 (36) |
| Smoking history | | | | | | |
| never | 1813 (41) | 350 (40) | 366 (42) | 391 (45) | 384 (43) | 322 (36) |
| former | 1918 (44) | 371 (42) | 362 (42) | 369 (42) | 376 (42) | 440 (49) |
| current | 673 (15) | 157 (18) | 138 (16) | 108 (12) | 140 (16) | 130 (15) |
| Medication Use | | | | | | |
| RASi | 3713 (84) | 739 (84) | 724 (83) | 711 (81) | 778 (86) | 761 (85) |
| Statins | 2155 (49) | 349 (40) | 391 (45) | 403 (46) | 485 (54) | 527 (59) |
| Anti-platelet agents | 1564 (36) | 180 (20) | 253 (29) | 332 (38) | 400 (44) | 399 (45) |
| Beta-blockers | 2480 (57) | 263 (30) | 376 (43) | 499 (57) | 624 (69) | 718 (80) |
| MRA | 364 (8) | 53 (6) | 50 (6) | 53 (6) | 79 (9) | 129 (14) |

Continuous variables are presented as mean and standard deviation or median and interquartile range.

Categorical variables are presented as numbers with percentages in the overall study population.

eGFR=estimated glomerular filtration rate, UACR=urinary albumin excretion rate, hsCRP=high sensitive C-reactive protein, LDL=low density lipoprotein, HDL=high density lipoprotein, BP=blood pressure, BMI=body mass index, CVD=cardiovascular disease, RASi=renin angiotensin system inhibitor, MRA=mineralocorticoid receptor antagonist

Table S3 Models A and Models B for Copeptin (showing all included variables)

| | | Non-cardiovascular death | Cardiovascular death | Major adverse cardiovascular event | Hospitalization for Heart Failure |
|--|----------------|--------------------------|----------------------|------------------------------------|-----------------------------------|
| | | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Adjusted model A^a | | | | | |
| Copeptin HR per SD increase | | 1.31 [1.24; 1.39] | 1.39 [1.28; 1.49] | 1.24 [1.16; 1.32] | 1.35 [1.28; 1.43] |
| Age (ys) | | 1.07 [1.06; 1.09] | 1.08 [1.06; 1.11] | 1.05 [1.04; 1.06] | 1.08 [1.06; 1.09] |
| gender | female | 0.70 [0.56; 0.87] | 0.47 [0.32; 0.69] | 0.54 [0.44; 0.66] | 0.80 [0.64; 0.99] |
| Copeptin (pmol/l) | Q2 | 1.27 [0.82; 1.96] | 2.29 [1.02; 5.17] | 1.31 [0.94; 1.85] | 1.42 [0.90; 2.25] |
| | Q3 | 2.10 [1.40; 3.13] | 2.49 [1.12; 5.54] | 1.29 [0.92; 1.82] | 2.27 [1.48; 3.47] |
| | Q4 | 2.35 [1.58; 3.49] | 3.68 [1.70; 7.95] | 1.81 [1.30; 2.51] | 2.60 [1.72; 3.95] |
| | Q5 | 3.70 [2.54; 5.41] | 8.08 [3.86; 16.87] | 2.54 [1.86; 3.48] | 4.72 [3.18; 7.02] |
| Age (ys) | | 1.07 [1.06; 1.08] | 1.08 [1.06; 1.10] | 1.05 [1.04; 1.06] | 1.07 [1.06; 1.09] |
| gender | female | 0.76 [0.60; 0.95] | 0.54 [0.38; 0.78] | 0.57 [0.46; 0.70] | 0.87 [0.70; 1.09] |
| Adjusted model B^b | | | | | |
| Copeptin HR per SD increase | | 1.19 [1.08; 1.32] | 1.29 [1.12; 1.48] | 1.10 [1.00; 1.21] | 1.30 [1.18; 1.43] |
| Age (ys) | | 1.06 [1.04; 1.08] | 1.05 [1.02; 1.08] | 1.03 [1.02; 1.04] | 1.06 [1.04; 1.08] |
| gender | female | 0.79 [0.62; 1.02] | 0.56 [0.36; 0.84] | 0.60 [0.48; 0.76] | 0.89 [0.70; 1.14] |
| Heart Failure | unknown | 1.33 [0.86; 2.06] | 0.79 [0.36; 1.72] | 1.10 [0.74; 1.63] | 1.87 [1.24; 2.80] |
| | yes | 1.93 [1.52; 2.44] | 1.50 [1.06; 2.11] | 1.31 [1.06; 1.62] | 2.17 [1.72; 2.74] |
| BMI (kg/m ²) | | 1.00 [0.98; 1.02] | 1.00 [0.98; 1.03] | 1.00 [0.98; 1.02] | 1.03 [1.02; 1.05] |
| Systolic BP (mmHg) | | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] |
| LDL cholesterol (mg/dl) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Diabetes | yes | 1.78 [1.42; 2.23] | 2.44 [1.70; 3.49] | 1.71 [1.40; 2.08] | 1.72 [1.36; 2.18] |
| eGFR (ml/min per 1.73 m ²) | | 0.99 [0.98; 1.00] | 0.98 [0.96; 0.99] | 0.99 [0.98; 0.99] | 0.99 [0.98; 1.00] |
| UACR (mg/g) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Previous CVD | yes | 1.23 [0.96; 1.56] | 2.03 [1.42; 2.90] | 1.73 [1.40; 2.14] | 1.62 [1.28; 2.05] |
| Smoking history | current smoker | 2.71 [1.98; 3.70] | 1.27 [0.76; 2.11] | 1.39 [1.06; 1.84] | 1.77 [1.28; 2.45] |
| | former smoker | 1.34 [1.04; 1.72] | 0.95 [0.66; 1.35] | 0.97 [0.78; 1.19] | 1.01 [0.78; 1.30] |
| hsCRP (mg/dl) | | 1.02 [1.00; 1.02] | 1.02 [1.00; 1.03] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| Statins | yes | 0.70 [0.56; 0.89] | 0.74 [0.52; 1.06] | 0.93 [0.76; 1.14] | 0.88 [0.70; 1.13] |
| RASi | yes | 0.76 [0.58; 1.02] | 1.40 [0.80; 2.45] | 1.14 [0.84; 1.53] | 1.27 [0.88; 1.82] |
| Anti-platelet agents | yes | 0.83 [0.66; 1.05] | 1.08 [0.76; 1.53] | 1.39 [1.12; 1.71] | 0.84 [0.66; 1.06] |
| Beta-blockers | yes | 1.18 [0.92; 1.49] | 1.40 [0.94; 2.08] | 1.25 [1.02; 1.55] | 1.72 [1.32; 2.26] |
| MRA | yes | 1.08 [0.78; 1.50] | 2.23 [1.50; 3.31] | 1.14 [0.84; 1.53] | 1.73 [1.30; 2.30] |
| regional center | AA | 1.02 [0.68; 1.54] | 0.58 [0.30; 1.16] | 0.60 [0.40; 0.91] | 0.59 [0.38; 0.93] |
| | BE | 1.07 [0.72; 1.59] | 0.64 [0.34; 1.17] | 1.03 [0.74; 1.44] | 0.68 [0.46; 1.01] |
| | FR | 1.06 [0.66; 1.67] | 1.14 [0.62; 2.13] | 0.79 [0.52; 1.20] | 0.67 [0.40; 1.10] |
| | HA | 0.97 [0.60; 1.56] | 0.59 [0.28; 1.27] | 0.79 [0.52; 1.22] | 0.52 [0.30; 0.88] |
| | HE | 1.49 [1.00; 2.21] | 0.29 [0.10; 0.82] | 0.62 [0.40; 0.96] | 0.47 [0.26; 0.81] |
| | JE | 0.89 [0.62; 1.30] | 0.80 [0.48; 1.35] | 0.90 [0.66; 1.23] | 0.79 [0.56; 1.11] |
| | MU | 0.78 [0.50; 1.23] | 0.98 [0.54; 1.76] | 0.91 [0.64; 1.31] | 0.87 [0.58; 1.31] |
| | WU | 0.93 [0.66; 1.30] | 0.95 [0.60; 1.48] | 1.14 [0.88; 1.49] | 0.77 [0.56; 1.06] |
| Copeptin (pmol/l) | Q2 | 1.02 [0.64; 1.64] | 1.31 [0.56; 3.02] | 1.05 [0.74; 1.51] | 1.06 [0.66; 1.72] |

| | | | | | |
|--|----------------|-------------------|-------------------|-------------------|-------------------|
| | Q3 | 1.58 [1.02; 2.44] | 1.31 [0.58; 2.98] | 0.90 [0.62; 1.29] | 1.47 [0.94; 2.32] |
| | Q4 | 1.53 [0.98; 2.37] | 1.94 [0.88; 4.30] | 1.28 [0.90; 1.83] | 1.56 [0.98; 2.46] |
| | Q5 | 2.01 [1.30; 3.14] | 2.91 [1.32; 6.44] | 1.39 [0.96; 2.01] | 2.36 [1.50; 3.74] |
| Age (ys) | | 1.06 [1.04; 1.08] | 1.05 [1.02; 1.08] | 1.03 [1.02; 1.04] | 1.06 [1.04; 1.08] |
| gender | female | 0.82 [0.64; 1.06] | 0.59 [0.38; 0.90] | 0.62 [0.48; 0.78] | 0.91 [0.70; 1.17] |
| Heart Failure | unknown | 1.35 [0.88; 2.09] | 0.78 [0.36; 1.70] | 1.09 [0.74; 1.61] | 1.90 [1.26; 2.85] |
| | yes | 1.93 [1.52; 2.44] | 1.48 [1.06; 2.09] | 1.31 [1.06; 1.61] | 2.18 [1.72; 2.75] |
| BMI (kg/m ²) | | 1.00 [0.98; 1.02] | 1.00 [0.98; 1.03] | 1.00 [0.98; 1.02] | 1.03 [1.02; 1.05] |
| Systolic BP (mmHg) | | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] |
| LDL cholesterol (mg/dl) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Diabetes | yes | 1.73 [1.38; 2.17] | 2.30 [1.60; 3.31] | 1.68 [1.38; 2.05] | 1.66 [1.32; 2.11] |
| eGFR (ml/min per 1.73 m ²) | | 0.99 [0.98; 1.00] | 0.98 [0.96; 0.99] | 0.99 [0.98; 0.99] | 0.99 [0.98; 1.00] |
| UACR (mg/g) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Previous CVD | yes | 1.21 [0.96; 1.54] | 1.99 [1.40; 2.84] | 1.73 [1.40; 2.14] | 1.58 [1.24; 2.01] |
| Smoking history | current smoker | 2.63 [1.92; 3.59] | 1.24 [0.74; 2.05] | 1.38 [1.04; 1.83] | 1.72 [1.24; 2.38] |
| | former smoker | 1.34 [1.04; 1.73] | 0.96 [0.68; 1.37] | 0.97 [0.78; 1.19] | 1.01 [0.80; 1.30] |
| hsCRP (mg/dl) | | 1.02 [1.00; 1.02] | 1.02 [1.00; 1.03] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| Statins | yes | 0.71 [0.56; 0.90] | 0.75 [0.52; 1.07] | 0.92 [0.74; 1.13] | 0.90 [0.70; 1.15] |
| RASi | yes | 0.75 [0.56; 1.00] | 1.38 [0.80; 2.42] | 1.14 [0.84; 1.54] | 1.24 [0.86; 1.78] |
| Anti-platelet agents | yes | 0.84 [0.66; 1.06] | 1.12 [0.80; 1.58] | 1.41 [1.14; 1.75] | 0.85 [0.68; 1.07] |
| Beta-blockers | yes | 1.16 [0.92; 1.47] | 1.37 [0.92; 2.03] | 1.24 [1.00; 1.54] | 1.69 [1.30; 2.22] |
| MRA | yes | 1.07 [0.78; 1.49] | 2.14 [1.44; 3.18] | 1.12 [0.84; 1.51] | 1.70 [1.28; 2.26] |
| regional center | AA | 1.01 [0.66; 1.52] | 0.57 [0.30; 1.14] | 0.59 [0.38; 0.89] | 0.59 [0.38; 0.92] |
| | BE | 1.06 [0.72; 1.56] | 0.63 [0.34; 1.15] | 1.02 [0.72; 1.42] | 0.68 [0.46; 1.00] |
| | FR | 1.03 [0.64; 1.63] | 1.08 [0.58; 2.01] | 0.78 [0.52; 1.19] | 0.63 [0.38; 1.04] |
| | HA | 0.95 [0.58; 1.53] | 0.57 [0.26; 1.24] | 0.78 [0.50; 1.21] | 0.51 [0.30; 0.86] |
| | HE | 1.46 [0.98; 2.16] | 0.27 [0.10; 0.77] | 0.60 [0.38; 0.94] | 0.45 [0.26; 0.78] |
| | JE | 0.88 [0.60; 1.27] | 0.77 [0.46; 1.30] | 0.89 [0.64; 1.22] | 0.77 [0.54; 1.09] |
| | MU | 0.78 [0.50; 1.24] | 0.95 [0.52; 1.72] | 0.90 [0.62; 1.30] | 0.87 [0.58; 1.30] |
| | WU | 0.94 [0.68; 1.31] | 0.94 [0.60; 1.47] | 1.13 [0.86; 1.48] | 0.77 [0.56; 1.06] |

Results are presented as hazard ratios with 95%-confidence intervals given in parentheses

^a model A: all models adjusted for age, gender,

^b model B: all models adjusted for age, gender, BMI, systolic BP, LDL cholesterol, diabetes, eGFR, UACR, smoking, hs-CRP, preexisting CVD, history of heart failure, CV medication, i.e. use of statins, RASi, anti-platelet agents, beta-blockers, and mineralocorticoid receptor antagonists and regional center.

^c SD Copeptin 11.7 pmol/l (whole population),

^d SD for MR-proANP 109.04 pmol/l (whole population),

^e SD for NT-proBNP 1073.4 pg/ml (whole population)

Table S4 Models A and Models B for MR-proANP (showing all included variables)

| | | Non-cardiovascular death | Cardiovascular death | Major adverse cardiovascular event | Hospitalization for Heart Failure |
|--|----------------|--------------------------|----------------------|------------------------------------|-----------------------------------|
| | | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Adjusted model A^a | | | | | |
| MR-proANP HR per SD increase | | 1.51 [1.42; 1.60] | 1.68 [1.56; 1.82] | 1.40 [1.32; 1.49] | 1.68 [1.58; 1.79] |
| Age (ys) | | 1.06 [1.04; 1.07] | 1.06 [1.04; 1.08] | 1.04 [1.04; 1.05] | 1.06 [1.04; 1.07] |
| gender | female | 0.65 [0.52; 0.81] | 0.45 [0.32; 0.65] | 0.51 [0.42; 0.62] | 0.75 [0.60; 0.93] |
| MR-proANP (pmol/l) | Q2 | 0.98 [0.62; 1.58] | 1.17 [0.52; 2.65] | 0.91 [0.62; 1.31] | 1.08 [0.60; 1.93] |
| | Q3 | 1.45 [0.94; 2.23] | 1.62 [0.76; 3.44] | 1.44 [1.04; 2.02] | 2.25 [1.36; 3.76] |
| | Q4 | 1.91 [1.26; 2.89] | 1.92 [0.92; 3.99] | 1.51 [1.08; 2.11] | 3.11 [1.90; 5.09] |
| | Q5 | 4.20 [2.84; 6.20] | 7.30 [3.74; 14.24] | 2.83 [2.08; 3.88] | 7.77 [4.84; 12.48] |
| Age (ys) | | 1.05 [1.04; 1.06] | 1.05 [1.04; 1.08] | 1.04 [1.02; 1.05] | 1.05 [1.04; 1.06] |
| gender | female | 0.63 [0.52; 0.78] | 0.43 [0.30; 0.61] | 0.50 [0.40; 0.61] | 0.71 [0.58; 0.88] |
| Adjusted model B^b | | | | | |
| MR-proANP HR per SD increase | | 1.41 [1.30; 1.52] | 1.54 [1.38; 1.71] | 1.25 [1.16; 1.36] | 1.58 [1.46; 1.71] |
| Age (ys) | | 1.06 [1.04; 1.07] | 1.05 [1.02; 1.07] | 1.03 [1.02; 1.04] | 1.05 [1.04; 1.07] |
| gender | female | 0.75 [0.58; 0.95] | 0.52 [0.34; 0.79] | 0.59 [0.46; 0.73] | 0.83 [0.64; 1.06] |
| Heart Failure | unknown | 1.24 [0.80; 1.92] | 0.81 [0.38; 1.76] | 1.11 [0.76; 1.65] | 1.87 [1.24; 2.8] |
| | yes | 1.77 [1.40; 2.24] | 1.45 [1.04; 2.03] | 1.27 [1.02; 1.57] | 2.04 [1.62; 2.57] |
| BMI (kg/m ²) | | 1.01 [1.00; 1.03] | 1.02 [0.98; 1.05] | 1.00 [0.98; 1.02] | 1.05 [1.02; 1.06] |
| Systolic BP (mmHg) | | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.00] |
| LDL cholesterol (mg/dl) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Diabetes | yes | 1.91 [1.52; 2.40] | 2.71 [1.90; 3.87] | 1.75 [1.44; 2.14] | 1.96 [1.56; 2.47] |
| eGFR (ml/min per 1.73 m ²) | | 0.99 [0.98; 1.00] | 0.98 [0.98; 1.00] | 0.99 [0.98; 1.00] | 1.00 [0.98; 1.01] |
| UACR (mg/g) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Previous CVD | yes | 1.11 [0.88; 1.42] | 1.78 [1.24; 2.55] | 1.64 [1.32; 2.03] | 1.44 [1.12; 1.83] |
| Smoking history | current smoker | 2.85 [2.08; 3.89] | 1.38 [0.82; 2.30] | 1.43 [1.08; 1.89] | 1.92 [1.38; 2.67] |
| | former smoker | 1.33 [1.04; 1.71] | 0.92 [0.64; 1.31] | 0.95 [0.78; 1.18] | 0.98 [0.76; 1.25] |
| hsCRP (mg/dl) | | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.03] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| Statins | yes | 0.70 [0.56; 0.89] | 0.72 [0.50; 1.03] | 0.92 [0.74; 1.13] | 0.88 [0.68; 1.12] |
| RASi | yes | 0.76 [0.58; 1.01] | 1.43 [0.82; 2.49] | 1.15 [0.86; 1.54] | 1.30 [0.90; 1.87] |
| Anti-platelet agents | yes | 0.93 [0.74; 1.17] | 1.21 [0.86; 1.71] | 1.45 [1.18; 1.78] | 0.94 [0.74; 1.19] |
| Beta-blockers | yes | 0.98 [0.76; 1.25] | 1.09 [0.74; 1.63] | 1.12 [0.90; 1.39] | 1.35 [1.02; 1.77] |
| MRA | yes | 1.04 [0.76; 1.45] | 2.10 [1.42; 3.11] | 1.11 [0.82; 1.49] | 1.68 [1.26; 2.23] |
| regional center | AA | 1.07 [0.70; 1.63] | 0.68 [0.34; 1.35] | 0.63 [0.40; 0.96] | 0.67 [0.42; 1.06] |
| | BE | 1.20 [0.82; 1.78] | 0.81 [0.44; 1.49] | 1.13 [0.80; 1.58] | 0.83 [0.56; 1.23] |
| | FR | 1.18 [0.74; 1.87] | 1.42 [0.76; 2.67] | 0.86 [0.56; 1.30] | 0.80 [0.48; 1.33] |
| | HA | 1.04 [0.64; 1.68] | 0.66 [0.30; 1.42] | 0.85 [0.54; 1.30] | 0.61 [0.36; 1.03] |
| | HE | 1.54 [1.04; 2.28] | 0.30 [0.10; 0.84] | 0.64 [0.40; 0.99] | 0.52 [0.30; 0.90] |
| | JE | 0.97 [0.66; 1.40] | 0.94 [0.56; 1.60] | 0.96 [0.70; 1.32] | 0.93 [0.66; 1.32] |
| | MU | 0.83 [0.52; 1.31] | 1.18 [0.64; 2.15] | 0.96 [0.66; 1.39] | 0.97 [0.64; 1.47] |
| | WU | 0.99 [0.70; 1.39] | 1.05 [0.66; 1.65] | 1.21 [0.92; 1.58] | 0.88 [0.64; 1.20] |

| | | | | | |
|--|----------------|-------------------|-------------------|-------------------|--------------------|
| MR-proANP (pmol/l) | Q2 | 0.87 [0.54; 1.42] | 1.14 [0.50; 2.57] | 0.80 [0.54; 1.17] | 1.23 [0.68; 2.25] |
| | Q3 | 1.14 [0.72; 1.80] | 1.26 [0.60; 2.71] | 1.15 [0.80; 1.63] | 2.08 [1.20; 3.60] |
| | Q4 | 1.47 [0.94; 2.28] | 1.13 [0.52; 2.42] | 1.00 [0.70; 1.43] | 2.74 [1.60; 4.69] |
| | Q5 | 2.72 [1.76; 4.20] | 3.70 [1.82; 7.51] | 1.66 [1.16; 2.36] | 6.03 [3.54; 10.28] |
| | Age (ys) | 1.05 [1.04; 1.07] | 1.04 [1.02; 1.07] | 1.03 [1.02; 1.04] | 1.05 [1.04; 1.07] |
| gender | female | 0.74 [0.58; 0.95] | 0.51 [0.34; 0.76] | 0.58 [0.46; 0.73] | 0.81 [0.64; 1.04] |
| Heart Failure | unknown | 1.27 [0.82; 1.97] | 0.79 [0.36; 1.72] | 1.11 [0.76; 1.65] | 1.76 [1.18; 2.64] |
| | yes | 1.80 [1.42; 2.28] | 1.49 [1.06; 2.10] | 1.29 [1.04; 1.59] | 2.05 [1.62; 2.58] |
| BMI (kg/m ²) | | 1.01 [0.98; 1.03] | 1.01 [0.98; 1.03] | 1.00 [0.98; 1.02] | 1.04 [1.02; 1.06] |
| Systolic BP (mmHg) | | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.00] |
| LDL cholesterol (mg/dl) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Diabetes | yes | 1.86 [1.48; 2.33] | 2.58 [1.80; 3.69] | 1.74 [1.42; 2.12] | 1.86 [1.48; 2.35] |
| eGFR (ml/min per 1.73 m ²) | | 0.99 [0.98; 1.00] | 0.98 [0.96; 0.99] | 0.99 [0.98; 1.00] | 1.00 [1.00; 1.01] |
| UACR (mg/g) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Previous CVD | yes | 1.11 [0.88; 1.42] | 1.82 [1.26; 2.60] | 1.65 [1.34; 2.05] | 1.40 [1.10; 1.78] |
| Smoking history | current smoker | 2.85 [2.08; 3.90] | 1.29 [0.78; 2.16] | 1.42 [1.08; 1.88] | 1.96 [1.40; 2.72] |
| | former smoker | 1.31 [1.02; 1.69] | 0.89 [0.62; 1.28] | 0.96 [0.78; 1.18] | 1.01 [0.78; 1.29] |
| | smoker | 1.01 [1.00; 1.02] | 1.02 [1.00; 1.03] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| hsCRP (mg/dl) | | 1.01 [1.00; 1.02] | 1.02 [1.00; 1.03] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| Statins | yes | 0.71 [0.56; 0.90] | 0.74 [0.52; 1.06] | 0.92 [0.74; 1.13] | 0.89 [0.70; 1.13] |
| RASi | yes | 0.79 [0.60; 1.06] | 1.50 [0.86; 2.62] | 1.16 [0.86; 1.56] | 1.36 [0.96; 1.95] |
| Anti-platelet agents | yes | 0.90 [0.72; 1.13] | 1.24 [0.88; 1.75] | 1.45 [1.18; 1.79] | 0.96 [0.76; 1.21] |
| Beta-blockers | yes | 0.96 [0.74; 1.23] | 1.09 [0.72; 1.64] | 1.13 [0.90; 1.42] | 1.22 [0.92; 1.61] |
| MRA | yes | 1.05 [0.76; 1.46] | 2.24 [1.50; 3.32] | 1.12 [0.84; 1.51] | 1.62 [1.22; 2.16] |
| regional center | AA | 1.04 [0.68; 1.59] | 0.60 [0.30; 1.18] | 0.60 [0.40; 0.92] | 0.60 [0.38; 0.94] |
| | BE | 1.09 [0.74; 1.61] | 0.65 [0.36; 1.19] | 1.06 [0.76; 1.48] | 0.71 [0.48; 1.05] |
| | FR | 1.06 [0.68; 1.68] | 1.16 [0.62; 2.17] | 0.80 [0.52; 1.22] | 0.66 [0.40; 1.10] |
| | HA | 1.00 [0.62; 1.61] | 0.63 [0.30; 1.37] | 0.81 [0.52; 1.25] | 0.53 [0.32; 0.90] |
| | HE | 1.43 [0.96; 2.13] | 0.27 [0.10; 0.77] | 0.60 [0.38; 0.94] | 0.44 [0.26; 0.77] |
| | JE | 0.92 [0.64; 1.34] | 0.84 [0.50; 1.41] | 0.92 [0.66; 1.26] | 0.86 [0.60; 1.21] |
| | MU | 0.82 [0.52; 1.30] | 1.15 [0.64; 2.08] | 0.93 [0.64; 1.35] | 0.92 [0.62; 1.39] |
| | WU | 0.92 [0.66; 1.28] | 0.92 [0.58; 1.44] | 1.15 [0.88; 1.51] | 0.77 [0.56; 1.06] |

Results are presented as hazard ratios with 95%-confidence intervals given in parentheses

^a model A: all models adjusted for age, gender,

^b model B: all models adjusted for age, gender, BMI, systolic BP, LDL cholesterol, diabetes, eGFR, UACR, smoking, hs-CRP, preexisting CVD, history of heart failure, CV medication, i.e. use of statins, RASi, anti-platelet agents, beta-blockers, and mineralocorticoid receptor antagonists and regional center.

^c SD Copeptin 11.7 pmol/l (whole population),

^d SD for MR-proANP 109.04 pmol/l (whole population),

^e SD for NT-proBNP 1073.4 pg/ml (whole population)

Table S5 Models A and Models B for NT-proBNP (showing all included variables)

| | | Non-cardiovascular death | Cardiovascular death | Major adverse cardiovascular event | Hospitalization for Heart Failure |
|--|----------------|--------------------------|----------------------|------------------------------------|-----------------------------------|
| | | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Adjusted model A^a | | | | | |
| NT-proBNP HR per SD increase | | 1.20 [1.16; 1.24] | 1.28 [1.24; 1.32] | 1.23 [1.20; 1.27] | 1.38 [1.32; 1.42] |
| Age (ys) | | 1.07 [1.06; 1.08] | 1.08 [1.06; 1.10] | 1.05 [1.04; 1.06] | 1.07 [1.06; 1.09] |
| gender | female | 0.60 [0.48; 0.75] | 0.38 [0.26; 0.54] | 0.49 [0.40; 0.60] | 0.69 [0.56; 0.86] |
| NT-proBNP (pg/ml) | Q2 | 1.67 [1.00; 2.80] | 1.19 [0.50; 2.85] | 1.27 [0.86; 1.87] | 2.40 [1.16; 4.97] |
| | Q3 | 2.06 [1.24; 3.39] | 0.94 [0.38; 2.34] | 1.45 [1.00; 2.11] | 3.30 [1.64; 6.63] |
| | Q4 | 3.35 [2.10; 5.38] | 2.56 [1.20; 5.48] | 2.45 [1.72; 3.47] | 7.66 [3.96; 14.81] |
| | Q5 | 7.59 [4.82; 11.96] | 11.26 [5.60; 22.69] | 4.56 [3.26; 6.36] | 21.96 [11.52; 41.82] |
| Age (ys) | | 1.05 [1.04; 1.06] | 1.05 [1.02; 1.07] | 1.03 [1.02; 1.05] | 1.04 [1.02; 1.06] |
| gender | female | 0.60 [0.48; 0.75] | 0.42 [0.30; 0.60] | 0.48 [0.40; 0.58] | 0.66 [0.54; 0.82] |
| Adjusted model B^b | | | | | |
| NT-proBNP HR per SD increase | | 1.14 [1.08; 1.19] | 1.25 [1.18; 1.32] | 1.17 [1.12; 1.23] | 1.32 [1.26; 1.37] |
| Age (ys) | | 1.06 [1.04; 1.08] | 1.05 [1.02; 1.08] | 1.03 [1.02; 1.04] | 1.06 [1.04; 1.08] |
| gender | female | 0.72 [0.56; 0.92] | 0.47 [0.30; 0.70] | 0.57 [0.46; 0.72] | 0.77 [0.60; 0.99] |
| Heart Failure | unknown | 1.24 [0.80; 1.94] | 0.71 [0.32; 1.58] | 1.11 [0.76; 1.64] | 1.87 [1.24; 2.80] |
| | yes | 1.90 [1.50; 2.41] | 1.46 [1.04; 2.04] | 1.26 [1.02; 1.56] | 2.11 [1.68; 2.66] |
| BMI (kg/m ²) | | 1.01 [0.98; 1.03] | 1.02 [0.98; 1.05] | 1.01 [0.98; 1.02] | 1.05 [1.02; 1.07] |
| Systolic BP (mmHg) | | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.00] |
| LDL cholesterol (mg/dl) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Diabetes | yes | 1.85 [1.48; 2.32] | 2.55 [1.78; 3.65] | 1.69 [1.38; 2.06] | 1.76 [1.40; 2.22] |
| eGFR (ml/min per 1.73 m ²) | | 0.98 [0.98; 0.99] | 0.98 [0.96; 0.99] | 0.99 [0.98; 0.99] | 0.99 [0.98; 1.00] |
| UACR (mg/g) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Previous CVD | yes | 1.19 [0.94; 1.51] | 1.87 [1.30; 2.68] | 1.65 [1.34; 2.04] | 1.49 [1.16; 1.89] |
| Smoking history | current smoker | 2.63 [1.92; 3.6] | 1.18 [0.70; 1.97] | 1.36 [1.02; 1.80] | 1.71 [1.22; 2.38] |
| | former smoker | 1.31 [1.02; 1.69] | 0.88 [0.62; 1.26] | 0.94 [0.76; 1.16] | 0.99 [0.76; 1.27] |
| hsCRP (mg/dl) | | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| Statins | yes | 0.72 [0.58; 0.92] | 0.78 [0.54; 1.12] | 0.94 [0.76; 1.17] | 0.92 [0.72; 1.18] |
| RASi | yes | 0.76 [0.56; 1.01] | 1.45 [0.82; 2.54] | 1.14 [0.84; 1.53] | 1.28 [0.90; 1.84] |
| Anti-platelet agents | yes | 0.85 [0.68; 1.07] | 1.14 [0.80; 1.61] | 1.43 [1.16; 1.76] | 0.92 [0.72; 1.17] |
| Beta-blockers | yes | 1.12 [0.88; 1.42] | 1.24 [0.84; 1.84] | 1.19 [0.96; 1.47] | 1.55 [1.18; 2.03] |
| MRA | yes | 1.07 [0.78; 1.49] | 2.11 [1.42; 3.12] | 1.09 [0.82; 1.47] | 1.59 [1.20; 2.12] |
| regional center | AA | 1.02 [0.68; 1.55] | 0.65 [0.32; 1.29] | 0.64 [0.42; 0.99] | 0.64 [0.40; 1.01] |
| | BE | 1.16 [0.78; 1.71] | 0.81 [0.44; 1.50] | 1.17 [0.84; 1.64] | 0.82 [0.56; 1.21] |
| | FR | 1.10 [0.70; 1.74] | 1.36 [0.72; 2.56] | 0.87 [0.56; 1.32] | 0.74 [0.44; 1.23] |
| | HA | 1.05 [0.64; 1.69] | 0.73 [0.34; 1.60] | 0.88 [0.58; 1.36] | 0.62 [0.36; 1.05] |
| | HE | 1.61 [1.08; 2.39] | 0.36 [0.12; 1.01] | 0.68 [0.44; 1.06] | 0.55 [0.32; 0.96] |
| | JE | 0.94 [0.64; 1.37] | 0.95 [0.56; 1.62] | 0.98 [0.72; 1.35] | 0.89 [0.64; 1.26] |
| | MU | 0.83 [0.52; 1.31] | 1.18 [0.64; 2.14] | 0.99 [0.68; 1.43] | 0.96 [0.64; 1.45] |
| | WU | 0.97 [0.70; 1.35] | 1.06 [0.68; 1.66] | 1.23 [0.94; 1.61] | 0.81 [0.60; 1.11] |

| | | | | | |
|--|----------------|-------------------|--------------------|-------------------|---------------------|
| NT-proBNP (pg/ml) | Q2 | 1.80 [1.02; 3.16] | 0.98 [0.40; 2.35] | 1.08 [0.72; 1.60] | 1.87 [0.90; 3.94] |
| | Q3 | 2.11 [1.22; 3.66] | 0.66 [0.26; 1.67] | 1.09 [0.74; 1.61] | 2.58 [1.26; 5.26] |
| | Q4 | 2.99 [1.76; 5.07] | 1.44 [0.66; 3.18] | 1.61 [1.10; 2.33] | 5.21 [2.64; 10.25] |
| | Q5 | 5.73 [3.38; 9.68] | 4.99 [2.36; 10.53] | 2.56 [1.76; 3.72] | 12.72 [6.50; 24.88] |
| | Age (ys) | 1.05 [1.04; 1.07] | 1.04 [1.02; 1.07] | 1.02 [1.02; 1.04] | 1.04 [1.02; 1.06] |
| gender | female | 0.68 [0.54; 0.87] | 0.48 [0.32; 0.72] | 0.56 [0.44; 0.70] | 0.72 [0.56; 0.92] |
| Heart Failure | unknown | 1.22 [0.80; 1.90] | 0.75 [0.34; 1.64] | 1.06 [0.72; 1.56] | 1.69 [1.12; 2.53] |
| | yes | 1.66 [1.32; 2.10] | 1.32 [0.94; 1.86] | 1.20 [0.98; 1.49] | 1.85 [1.46; 2.33] |
| BMI (kg/m ²) | | 1.01 [1.00; 1.03] | 1.01 [0.98; 1.04] | 1.00 [0.98; 1.02] | 1.04 [1.02; 1.06] |
| Systolic BP (mmHg) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.01] | 1.00 [1.00; 1.00] |
| LDL cholesterol (mg/dl) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Diabetes | yes | 1.79 [1.42; 2.24] | 2.43 [1.70; 3.47] | 1.72 [1.40; 2.09] | 1.79 [1.42; 2.25] |
| eGFR (ml/min per 1.73 m ²) | | 0.99 [0.98; 1.00] | 0.98 [0.96; 0.99] | 0.99 [0.98; 1.00] | 1.00 [0.98; 1.00] |
| UACR (mg/g) | | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] | 1.00 [1.00; 1.00] |
| Previous CVD | yes | 1.02 [0.80; 1.31] | 1.58 [1.10; 2.27] | 1.53 [1.24; 1.90] | 1.23 [0.96; 1.57] |
| Smoking history | current smoker | 2.55 [1.86; 3.49] | 1.16 [0.70; 1.93] | 1.33 [1.00; 1.75] | 1.63 [1.18; 2.26] |
| | former smoker | 1.28 [1.00; 1.65] | 0.88 [0.62; 1.26] | 0.94 [0.76; 1.17] | 0.96 [0.74; 1.24] |
| | | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.03] | 1.01 [1.00; 1.02] | 1.01 [1.00; 1.02] |
| hsCRP (mg/dl) | | 0.71 [0.56; 0.90] | 0.75 [0.52; 1.08] | 0.92 [0.74; 1.13] | 0.86 [0.68; 1.10] |
| Statins | yes | 0.79 [0.60; 1.05] | 1.53 [0.88; 2.67] | 1.17 [0.88; 1.58] | 1.43 [1.00; 2.05] |
| RASi | yes | 0.91 [0.72; 1.15] | 1.33 [0.94; 1.87] | 1.47 [1.20; 1.81] | 1.01 [0.80; 1.28] |
| Anti-platelet agents | yes | 0.91 [0.72; 1.17] | 1.01 [0.68; 1.52] | 1.06 [0.86; 1.33] | 1.13 [0.86; 1.49] |
| Beta-blockers | yes | 0.96 [0.70; 1.34] | 1.88 [1.26; 2.80] | 1.03 [0.76; 1.39] | 1.42 [1.06; 1.89] |
| MRA | yes | 1.12 [0.74; 1.70] | 0.61 [0.30; 1.23] | 0.63 [0.42; 0.96] | 0.66 [0.42; 1.03] |
| regional center | AA | 1.21 [0.82; 1.78] | 0.77 [0.42; 1.41] | 1.12 [0.80; 1.57] | 0.80 [0.54; 1.17] |
| | BE | 0.98 [0.62; 1.55] | 1.01 [0.54; 1.89] | 0.74 [0.48; 1.13] | 0.58 [0.34; 0.96] |
| | FR | 1.03 [0.64; 1.67] | 0.65 [0.30; 1.40] | 0.83 [0.54; 1.27] | 0.56 [0.32; 0.95] |
| | HA | 1.45 [0.98; 2.16] | 0.27 [0.10; 0.78] | 0.59 [0.38; 0.93] | 0.43 [0.24; 0.75] |
| | HE | 0.92 [0.64; 1.33] | 0.83 [0.48; 1.40] | 0.92 [0.66; 1.26] | 0.83 [0.58; 1.17] |
| | JE | 0.78 [0.50; 1.23] | 0.97 [0.54; 1.75] | 0.91 [0.62; 1.31] | 0.86 [0.58; 1.30] |
| | MU | 0.93 [0.66; 1.31] | 0.93 [0.60; 1.46] | 1.16 [0.88; 1.51] | 0.77 [0.56; 1.06] |
| | WU | | | | |

Results are presented as hazard ratios with 95%-confidence intervals given in parentheses

^a model A: all models adjusted for age, gender,

^b model B: all models adjusted for age, gender, BMI, systolic BP, LDL cholesterol, diabetes, eGFR, UACR, smoking, hs-CRP, preexisting CVD, history of heart failure, CV medication, i.e. use of statins, RASi, anti-platelet agents, beta-blockers, and mineralocorticoid receptor antagonists and regional center.

^c SD Copeptin 11.7 pmol/l (whole population),

^d SD for MR-proANP 109.04 pmol/l (whole population),

^e SD for NT-proBNP 1073.4 pg/ml (whole population)